company background image
SANN

Santhera Pharmaceuticals Holding SWX:SANN Stock Report

Last Price

CHF0.80

Market Cap

CHF41.6m

7D

-6.4%

1Y

-61.2%

Updated

12 Aug, 2022

Data

Company Financials +
SANN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

SANN Stock Overview

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally.

Santhera Pharmaceuticals Holding AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Santhera Pharmaceuticals Holding
Historical stock prices
Current Share PriceCHF0.80
52 Week HighCHF2.66
52 Week LowCHF0.78
Beta1.19
1 Month Change-7.19%
3 Month Change-37.01%
1 Year Change-61.17%
3 Year Change-93.55%
5 Year Change-98.81%
Change since IPO-99.12%

Recent News & Updates

Shareholder Returns

SANNCH BiotechsCH Market
7D-6.4%-1.3%0.3%
1Y-61.2%-15.2%-12.5%

Return vs Industry: SANN underperformed the Swiss Biotechs industry which returned -14.3% over the past year.

Return vs Market: SANN underperformed the Swiss Market which returned -12% over the past year.

Price Volatility

Is SANN's price volatile compared to industry and market?
SANN volatility
SANN Average Weekly Movement6.3%
Biotechs Industry Average Movement13.0%
Market Average Movement4.5%
10% most volatile stocks in CH Market7.9%
10% least volatile stocks in CH Market2.4%

Stable Share Price: SANN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SANN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
200439Dario Eklundhttps://www.santhera.com

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company’s lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.

Santhera Pharmaceuticals Holding AG Fundamentals Summary

How do Santhera Pharmaceuticals Holding's earnings and revenue compare to its market cap?
SANN fundamental statistics
Market CapCHF41.59m
Earnings (TTM)-CHF55.53m
Revenue (TTM)n/a

-26.1x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SANN income statement (TTM)
Revenue-CHF1.59m
Cost of RevenueCHF3.77m
Gross Profit-CHF5.36m
Other ExpensesCHF50.16m
Earnings-CHF55.53m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin336.17%
Net Profit Margin3,481.25%
Debt/Equity Ratio3,099.7%

How did SANN perform over the long term?

See historical performance and comparison